X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
XIFAXAN (rifaximin) 200 mg tablets are indicated for travelers diarrhea. XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Rifaximin-Generic
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Salix Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
Salix going present two scientific posters featuring rifaximin data at the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting Digital Experience, which will take place.
Lead Product(s): Rifaximin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Company plans to start a Phase 2 trial in the first half of 2021 evaluating a novel rifaximin formulation for a potential sickle cell disease treatment.
Lead Product(s): Rifaximin
Therapeutic Area: Genetic Disease Product Name: Xifaxan
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Company to present 14 new abstract featuring research and data spanning Salix's GI portfolio – including rifaximin, plecanatide, methylnaltrexone bromide and PEG-3350.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
In the study, the treatment arm evaluating 40 mg BID of rifaximin SSD IR plus standard of care therapy met its primary endpoint of time to resolution of OHE.
Lead Product(s): Rifaximin,Lactulose
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
